Results 81 to 90 of about 32,071 (158)

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj  

Remdesivir and its antiviral activity against COVID-19: A systematic review

Clinical Epidemiology and Global Health, 2021
Background: The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. Methods: Available publications were systematically explored on some databases and gray literature was examined.
Andri Frediansyah, Firzan Nainu, Kuldeep Dhama, Mudatsir Mudatsir, Harapan Harapan   +4 more
doaj  

Pharmacokinetics of GS‐441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021–2024)

Journal of Small Animal Practice, Volume 66, Issue 7, Page 495-506, July 2025.
Objectives This study aimed to: (1) characterise the pharmacokinetics of GS‐441524 following intravenous (iv) administration of 15 mg/kg remdesivir (RDV) in client‐owned cats with feline infectious peritonitis (FIP); (2) document plasma protein binding of GS‐441524 in cats; (3) determine whether trough GS‐441524 plasma concentrations predict ‘simple ...
S. J. Coggins, M. Govendir, J. M. Norris, R. Malik, E. J. Hall, M. F. Thompson, B. Kimble   +6 more
wiley   +1 more source

Remdesivir in covid-19 [PDF]

BMJ, 2020
Ferner, Robin E, Aronson, Jeffrey K
openaire   +3 more sources

COVID‐19 and Liver Injury, Beyond the First Pandemic Waves: Clinical and Immune‐Virological Features

Journal of Viral Hepatitis, Volume 32, Issue 7, July 2025.
ABSTRACT A liver involvement in Coronavirus disease 19 (COVID‐19) has been frequently observed in patients hospitalised for severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) infection during 2020; in such cases, the clinical and prognostic relevance of hepatocellular damage has been widely acknowledged.
Luca Foroghi Biland, Andrea Di Lorenzo, Francesco De Maria, Gianmarco Muratore, Mirko Compagno, Laura Campogiani, Luigi Coppola, Elisabetta Teti, Vincenzo Malagnino, Marco Iannetta, Loredana Sarmati   +10 more
wiley   +1 more source

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj  

Safety and heart rate changes in Covid-19 patients treated with Remdesivir

International Journal of Infectious Diseases, 2021
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.
Natale Daniele Brunetti, MD, PhD, Mariacristina Poliseno, MD, Irene Francesca Bottalico, MD, Antonio Centola, MD, Laura Montemurro, MD, Salvatore Sica, MD, Teresa Santantonio, MD, Sergio Lo Caputo, MD   +7 more
doaj  

Remdesivir: A Review in COVID-19

Drugs, 2023
Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity, is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 infection. Unlike some antivirals, remdesivir has a low potential for drug-drug interactions. In the pivotal ACTT-1 trial
openaire   +2 more sources

A case report on the association between QTc prolongation and remdesivir therapy in a critically ill patient

IDCases, 2022
Remdesivir is a direct-acting inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase that is used to treat severe COVID-19 infections. We report a patient with severe COVID-19 pneumonia who experienced palpitations and syncope two days after starting ...
Shmeylan Al Harbi, Mashael AlFaifi, Hasan M. Al-Dorzi, Ohoud Aljuhani, Abeer A. Alenazi, Mai Alalawi, Khalid Al Sulaiman   +6 more
doaj  

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Journal of Infection and Public Health, 2021
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009.
Mohd. Imran, Ahmed Subeh Alshrari, Syed Mohammed Basheeruddin Asdaq, Abida   +3 more
doaj